Literature DB >> 35871433

Loureirin C and Xanthoceraside Prevent Abnormal Behaviors Associated with Downregulation of Brain Derived Neurotrophic Factor and AKT/mTOR/CREB Signaling in the Prefrontal Cortex Induced by Chronic Corticosterone Exposure in Mice.

Yang Yang1,2, Akihiro Mouri3,4, Qiaohui Lu1,2, Kazuo Kunisawa1, Hisayoshi Kubota1, Masaya Hasegawa1, Mami Hirakawa1, Yuko Mori5, Zou Libo2, Kuniaki Saito5,6, Toshitaka Nabeshima7,6.   

Abstract

Brain derived neurotrophic factor (BDNF) is one of the most abundant neurotrophic factors, and its deficits are involved in the pathogenesis of major depressive disorders (MDD). Loureirin C (Lou C) is a compound derived from red resin extracted from the stems of Chinese dragon's blood. Xanthoceraside (Xan) is a triterpenoid saponin extracted from the husks of Xanthoceras sorbifolia Bunge. These compounds have neuroprotective effects through upregulation of BDNF. The present study aimed to evaluate whether Lou C and Xan attenuate abnormal behaviors induced by chronic corticosterone (CORT) administration. CORT was administered subcutaneously to mice for 3 weeks, and Lou C and Xan, dispensed orally once a day during the last 2 weeks of CORT administration. Chronic CORT administration induced abnormal behaviors such as prolonged starting latency in the open field test, decreased social interaction time in the social interaction test and prolonged latency to eat in the novelty suppressed feeding test. Chronic CORT administration decreased the expression levels of BDNF and the phosphorylation of protein kinase B (Akt), mammalian target of rapamycin (mTOR), and the cAMP response element binding protein (CREB) in the prefrontal cortex. Lou C and Xan dose-dependently prevented the abnormal behaviors and decreased the expression levels of BDNF and in phosphorylation of AKT, mTOR, and CREB in the prefrontal cortex of CORT mice. These results suggest that Lou C and Xan could be attractive candidates for pharmacotherapy of MDD at least in part, given their propensity to increase BDNF expression and phosphorylation of AKT, mTOR, and CREB.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Brain-derived neurotrophic factor; Corticosterone; Depression; Loureirin C; Xanthoceraside

Mesh:

Substances:

Year:  2022        PMID: 35871433     DOI: 10.1007/s11064-022-03694-x

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   4.414


  65 in total

Review 1.  A neurotrophic model for stress-related mood disorders.

Authors:  Ronald S Duman; Lisa M Monteggia
Journal:  Biol Psychiatry       Date:  2006-04-21       Impact factor: 13.382

Review 2.  The costs of depression.

Authors:  Ronald C Kessler
Journal:  Psychiatr Clin North Am       Date:  2011-12-16

3.  NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression.

Authors:  P C Maisonpierre; L Belluscio; B Friedman; R F Alderson; S J Wiegand; M E Furth; R M Lindsay; G D Yancopoulos
Journal:  Neuron       Date:  1990-10       Impact factor: 17.173

4.  Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication.

Authors:  B Chen; D Dowlatshahi; G M MacQueen; J F Wang; L T Young
Journal:  Biol Psychiatry       Date:  2001-08-15       Impact factor: 13.382

5.  Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments.

Authors:  M Nibuya; S Morinobu; R S Duman
Journal:  J Neurosci       Date:  1995-11       Impact factor: 6.167

6.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

Review 7.  Social and economic burden of mood disorders.

Authors:  Gregory E Simon
Journal:  Biol Psychiatry       Date:  2003-08-01       Impact factor: 13.382

8.  Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects.

Authors:  Tommi Saarelainen; Panu Hendolin; Guilherme Lucas; Eija Koponen; Mikko Sairanen; Ewen MacDonald; Karin Agerman; Annakaisa Haapasalo; Hiroyuki Nawa; Raquel Aloyz; Patrik Ernfors; Eero Castrén
Journal:  J Neurosci       Date:  2003-01-01       Impact factor: 6.167

Review 9.  Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.

Authors:  George I Papakostas; Michael E Thase; Maurizio Fava; J Craig Nelson; Richard C Shelton
Journal:  Biol Psychiatry       Date:  2007-06-22       Impact factor: 13.382

Review 10.  Early Life Stress Effects on Glucocorticoid-BDNF Interplay in the Hippocampus.

Authors:  Nikolaos P Daskalakis; Edo Ronald De Kloet; Rachel Yehuda; Dolores Malaspina; Thorsten M Kranz
Journal:  Front Mol Neurosci       Date:  2015-11-16       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.